Larson Katelyn, Damon Melissa, Randhi Rajasa, Nixon-Lee Nancy, Dixon Kirsty J
Department of Surgery, Virginia Commonwealth University, 1101 E. Marshall Street, Richmond VA, 23298, USA.
CNS Neurol Disord Drug Targets. 2023;22(9):1378-1390. doi: 10.2174/1871527321666220610104908.
To determine the efficacy of XPro1595 to improve pathophysiological and functional outcomes in a mouse model of traumatic brain injury (TBI).
Symptoms associated with TBI can be debilitating, and treatment without off-target side effects remains a challenge. This study aimed to investigate the efficacy of selectively inhibiting the soluble form of TNF (solTNF) using the biologic XPro1595 in a mouse model of TBI.
Use XPro1595 to determine whether injury-induced solTNF promotes hippocampal inflammation and dendritic plasticity and associated functional impairments.
Mild-to-moderate traumatic brain injury (CCI model) was induced in adult male C57Bl/6J WT and Thy1-YFPH mice, with XPro1595 (10 mg/kg, S.C.) or vehicle being administered in a clinically relevant window (60 minutes post-injury). The animals were assessed for differences in neurological function, and hippocampal tissue was analyzed for inflammation and glial reactivity, as well as neuronal degeneration and plasticity.
We report that unilateral CCI over the right parietal cortex in mice promoted deficits in learning and memory, depressive-like behavior, and neuropathic pain. Using immunohistochemical and Western blotting techniques, we observed the cortical injury promoted a set of expected pathophysiology's within the hippocampus consistent with the observed neurological outcomes, including glial reactivity, enhanced neuronal dendritic degeneration (dendritic beading), and reduced synaptic plasticity (spine density and PSD-95 expression) within the DG and CA1 region of the hippocampus, that were prevented in mice treated with XPro1595.
Overall, we observed that selectively inhibiting solTNF using XPro1595 improved the pathophysiological and neurological sequelae of brain-injured mice, which provides support for its use in patients with TBI.
确定XPro1595在创伤性脑损伤(TBI)小鼠模型中改善病理生理和功能结局的疗效。
与TBI相关的症状可能使人衰弱,且无脱靶副作用的治疗仍然是一项挑战。本研究旨在调查在TBI小鼠模型中使用生物制剂XPro1595选择性抑制可溶性肿瘤坏死因子(solTNF)的疗效。
使用XPro1595确定损伤诱导的solTNF是否促进海马炎症、树突可塑性及相关功能障碍。
在成年雄性C57Bl/6J野生型和Thy1-YFPH小鼠中诱导轻度至中度创伤性脑损伤(控制性皮质撞击伤模型),在临床相关时间窗(损伤后60分钟)给予XPro1595(10mg/kg,皮下注射)或赋形剂。评估动物神经功能的差异,并分析海马组织的炎症、胶质细胞反应性以及神经元变性和可塑性。
我们报告,小鼠右侧顶叶皮质的单侧控制性皮质撞击伤导致学习和记忆缺陷、抑郁样行为和神经性疼痛。使用免疫组织化学和蛋白质印迹技术,我们观察到皮质损伤促进了海马内一系列与观察到的神经学结局一致的预期病理生理学变化,包括胶质细胞反应性、海马齿状回和CA1区神经元树突变性增强(树突串珠)以及突触可塑性降低(棘密度和PSD-95表达),而在用XPro1595治疗的小鼠中这些变化得到了预防。
总体而言,我们观察到使用XPro1595选择性抑制solTNF可改善脑损伤小鼠的病理生理和神经后遗症,这为其在TBI患者中的应用提供了支持。